Experimental gene therapy reduces seizures by 90% in drug-resistant epilepsy patients

Researchers in China used chemogenetics and clozapine to regulate brain activity in three patients with hippocampal sclerosis.

Researchers in China used a combination of experimental gene therapy and medication to reduce epileptic seizures by more than 90% in three patients with epilepsy resistant to conventional treatments. The trial resulted in an average reduction in seizure frequency of 92.6% across all three patients.

The patients all had hippocampal sclerosis, a condition involving scarring of the hippocampus, and had lived with epilepsy for between 10 and 25 years. All three had scarring on only one side of their brains. During surgery, researchers delivered an engineered adeno-associated virus 9 into the affected region to introduce a gene that made neurons responsive to the antipsychotic drug clozapine.

This chemogenetic approach allows the activity of genetically modified nerve cells to be controlled by administering a specific drug, which enables dosage adjustments. The modified neurons become less active when exposed to clozapine, helping suppress the abnormal electrical signals that cause seizures. Patients received low doses of clozapine every eight hours starting two weeks after surgery.

Around two months after treatment, the average monthly seizure frequency fell from 4.5 to 0.5 in two participants, while the third patient saw seizures drop from four per month to none. Researchers observed no serious adverse effects from the treatment.

Matthew Walker, a neurologist at University College London not involved in the research, said it is exciting that there is such a dramatic effect with very few side effects. However, Walker raised concerns about the small trial size and the long-term use of clozapine, which has been associated with cardiovascular problems at higher doses. The lack of a control group also makes it difficult to determine if improvements were solely due to the chemogenetic treatment.

The trial was small because it was intended to assess safety. Further trials involving more patients will be necessary to determine the treatment's safety and efficacy.

Key facts

  • Seizure frequency was reduced by an average of 92.6% in three patients.
  • The treatment used an engineered adeno-associated virus 9 to make neurons responsive to clozapine.
  • The trial was designed primarily to assess safety.

Three perspectives

Neutral

Researchers used chemogenetics to regulate electrical activity in the brains of three patients with drug-resistant epilepsy.

Positive

The experimental treatment reduced seizure frequency by more than 90% in patients resistant to conventional treatments.

Negative

The small trial size, lack of a control group, and potential cardiovascular risks associated with long-term clozapine use are concerns.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Next storyResearchers use pink noise to increase brain waste clearance during sleep

All sections

Edition